Evidence map›Paper›PMID 36158893›Full record

ArticleBioMed research international2022

SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition.

Sooyeon Kang, Ji Hye Kim, Jisoo Hong, Ji Hong Moon, Yun Young Kwon, Seong-Gyu Ko

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sooyeon KangDepartment of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.ORCID https://orcid.org/0000-0003-2745-9463
Ji Hye KimDepartment of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.ORCID https://orcid.org/0000-0003-0422-9315
Jisoo HongDepartment of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
Ji Hong MoonDepartment of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
Yun Young KwonDepartment of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
Seong-Gyu KoDepartment of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.ORCID https://orcid.org/0000-0002-2345-430X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we have examined the anticancer effects of SH005S7 on MET-amplified and (HCC827GR) NSCLC cells and their primary HCC827 cells.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsApoptosisBromodeoxyuridineCell Line, TumorCell ProliferationDrug Resistance, NeoplasmErbB ReceptorsGefitinibHumansKi-67 AntigenMatrix Metalloproteinase 9MiceMice, NudeProliferating Cell Nuclear AntigenBromodeoxyuridineEGFR protein, humanErbB ReceptorsGefitinibKi-67 AntigenMatrix Metalloproteinase 9Proliferating Cell Nuclear AntigenProtein Kinase InhibitorsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metQuinazolinesTumor Necrosis Factor-alphaVimentin

Identifiers

PMID36158893
PMCPMC9499774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.